Measuring Impact in Medical Affairs Summit on February 24-26, 2026 in Boston, United States

The Measuring Impact in Medical Affairs Summit is uniting Medical Affairs leaders from across pharma and biotech to define, benchmark, and standardize meaningful KPIs that capture the true value of Medical Affairs activities.

As Medical Affairs cements its role as the strategic bridge between R and D and commercialization, the pressure to quantify and communicate impact has never been greater. In an era of tighter budgets, digital transformation, and AI-driven analytics, teams must move beyond activity tracking to demonstrate measurable outcomes that drive scientific, stakeholder, and commercial success.

This year, join 50+ experts from Boehringer Ingelheim, Abbvie, Alexion, Travere, Regeneron, and more to explore how leading teams are designing metrics that reflect quality over quantity, leveraging AI to enhance insight generation, and co-creating the next generation of KPIs defining Medical Affairs excellence. Don’t miss the only meeting dedicated to transforming Medical Affairs from an activity-based to an impact-driven function.

URLs:
Brochure: https://go.evvnt.com/3347262-0?pid=10008
Tickets: https://go.evvnt.com/3347262-3?pid=10008

Time: 9:00 AM - 5:00 PM

Venue Details: Revere Hotel Boston Common, 200 Stuart Street, Boston, Massachusetts, 02116, United States

Category: Conferences | Science, Health and Medicine

Prices:

Drug Developer Pricing - Conference + Pre-Conference Workshop Day (save $1,000): USD 3397.00,

Drug Developer Pricing - Conference Only (save $500): USD 2599.00,

Academic Pricing - Conference + Pre-Conference Workshop Day (save $1,000): USD 2797.00,

Academic Pricing - Conference Only (save $500): USD 2199.00,

Service and Solution Provider Pricing - Conference + Pre-Conference Workshop Day (save $1,000): USD 4297.00,

Service and Solution Provider Pricing - Conference Only (save $500): USD 3299.00

Speakers: Denise Briggs, MSL Field Director, AbbVie, Rachel Markle, Senior Medical Science Liaison - Psychiatry, Abbvie, Christina Kotisi, Senior Director, Innovation Lead, Bayer, Bill Tidwell, Executive Director, Medical Engagement Group Lead, Boehringer Ingelheim, Greg Gillum, Director, Medical Impact and Data Enablement, Boehringer Ingelheim, Kimberly Barnholt, Executive Director - Medical Operations and Evidence Generation, Genentech, Nelli Oliver, Lead of Global Healthcare Analytics, Jazz Pharmaceuticals, Marcela Gaitan Mangas, Associate Director Medical Affairs, Regeneron, Robert Johnson, Portfolio Strategy Lead for Global Medical, Specialty Care, Sanofi, Sara Wood, Medical Transformation and New Product Planning Lead, Specialty Care NA Medical and MedDev Lead, Sanofi, Tiffany Pela, US Gastroenterology Medical Director, Sanofi, Julia Catini, Senior Director - Global Medical and Amyloidosis, Alexion Pharma, Terry Ferguson, Chief Medical Officer, Cadrenal Therapeutics, Selena Freisens, Head of Global Medical Affairs, Merz Therapeutics, Abhishek Sinha, Senior Director, Head of AI Visualization, Sage Therapeutics, Melissa Downey, Field Medical Director - Gene Therapy Taysha, Gene Therapies, Rachel Couchenour, Vice President, Global Medical Affairs, Travere Therapeutics, Erin Bretz, Global Medical Affairs - Medical Excellence Strategy and Process Lead, BioMarin